{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:24:30Z","timestamp":1784042670677,"version":"3.55.0"},"reference-count":138,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["201708110232"],"award-info":[{"award-number":["201708110232"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ijcard.2018.09.057","type":"journal-article","created":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T23:06:57Z","timestamp":1537398417000},"page":"201-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Stroke prevention in atrial fibrillation: State of the art"],"prefix":"10.1016","volume":"287","author":[{"given":"Yan-Guang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2018.09.057_bb0005","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0010","unstructured":"Heart disease \u2014 atrial fibrillation. Heart and Stroke Foundation of Canada http:\/\/www.heartandstroke.ca\/heart\/conditions\/atrial-fibrillation. Accessed 19 Jun 2016."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0015","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1161\/STROKEAHA.116.012865","article-title":"Atrial fibrillation is associated with a worse 90-day outcome than other cardioembolic stroke subtypes","volume":"47","author":"Henninger","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0020","doi-asserted-by":"crossref","first-page":"590","DOI":"10.7326\/0003-4819-147-8-200710160-00018","article-title":"Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation","volume":"147","author":"Hart","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164076","article-title":"Quality of vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF registry","volume":"11","author":"Haas","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0030","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation-ARISTOTLE study","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0035","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0040","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0045","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0050","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.amjcard.2015.12.027","article-title":"Meta-analysis of efficacy and safety of new oral anticoagulants compared with uninterrupted vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation","volume":"117","author":"Wu","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0055","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.hrthm.2017.09.011","article-title":"An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation","volume":"15","author":"Cardoso","year":"2018","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0060","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1161\/STROKEAHA.117.017549","article-title":"Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis","volume":"48","author":"Ntaios","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0065","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07853890.2018.1460489","article-title":"Fitting the right non-vitamin K antagonist oral anticoagulant to the right patient with non-valvular atrial fibrillation: an evidence-based choice","volume":"50","author":"Li","year":"2018","journal-title":"Ann. Med."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0075","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/jama.2017.21917","article-title":"Association of intracerebral hemorrhage among patients taking non-vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital mortality","volume":"319","author":"Inohara","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0080","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/jth.12845","article-title":"Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study","volume":"13","author":"Gorst-Rasmussen","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0085","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1160\/TH16-10-0757","article-title":"Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants","volume":"117","author":"Raparelli","year":"2017","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0090","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1160\/TH16-12-0961","article-title":"Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients","volume":"117","author":"Rivera-Caravaca","year":"2017","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0095","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.mayocp.2017.05.023","article-title":"Guideline-adherent antithrombotic treatment improves outcomes in patients with atrial fibrillation: insights from the community-based Darlington Atrial Fibrillation Registry","volume":"92","author":"Mazurek","year":"2017","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0100","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1160\/TH15-07-0565","article-title":"Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy","volume":"114","author":"Lip","year":"2015","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0105","unstructured":"Lip G, Freedman B, De Caterina R, Potpara TS. Stroke prevention in atrial fibrillation: past, present and future. Comparing the guidelines and practical decision-making. Thromb. Haemost. 2017;117:1230\u20139."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0110","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0115","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0120","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1161\/STROKEAHA.115.012609","article-title":"Ischemic stroke risk in patients with atrial fibrillation and CHA2DS2-VASc score of 1: systematic review and meta-analysis","volume":"47","author":"Joundi","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0125","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1378\/chest.15-1622","article-title":"Oral anticoagulation and the risk of stroke or death in patients with atrial fibrillation and one additional stroke risk factor: the Loire Valley Atrial Fibrillation Project","volume":"149","author":"Fauchier","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0130","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.jacc.2015.01.044","article-title":"Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score","volume":"65","author":"Lip","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0135","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacc.2014.11.046","article-title":"Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?","volume":"65","author":"Chao","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0140","first-page":"342","article-title":"Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study","volume":"d124","author":"Olesen","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0145","doi-asserted-by":"crossref","unstructured":"Lip GY, Nielsen PB. Should patients with atrial fibrillation and 1 stroke risk factor (CHA2DS2-VASc score 1 in men, 2 in women) be anticoagulated? Yes: even 1 stroke risk factor confers a real risk of stroke. Circulation 2016;133:1498\u2013503; (discussion 503).","DOI":"10.1161\/CIRCULATIONAHA.115.016713"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0150","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003839","article-title":"Is an oral anticoagulant necessary for young atrial fibrillation patients with a CHA2DS2-VASc score of 1 (men) or 2 (women)?","volume":"5","author":"Hung","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0155","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/STROKEAHA.116.013253","article-title":"Should atrial fibrillation patients with only 1 nongender-related CHA2DS2-VASc risk factor be anticoagulated?","volume":"47","author":"Fauchier","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0160","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1161\/CIRCOUTCOMES.110.958108","article-title":"Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation","volume":"4","author":"Eckman","year":"2011","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0165","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jacc.2017.10.085","article-title":"Relationship of aging and incident comorbidities to stroke risk in patients with atrial fibrillation","volume":"71","author":"Chao","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report","author":"Lip","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0175","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jacc.2015.07.026","article-title":"Age threshold for increased stroke risk among patients with atrial fibrillation: a nationwide cohort study from Taiwan","volume":"66","author":"Chao","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0180","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1161\/STROKEAHA.116.013880","article-title":"Validation of a modified CHA2DS2-VASc score for stroke risk stratification in Asian patients with atrial fibrillation: a nationwide cohort study","volume":"47","author":"Chao","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0185","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1161\/CIRCULATIONAHA.117.029081","article-title":"Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation: should we use a CHA2DS2-VA score rather than CHA2DS2-VASc?","volume":"137","author":"Nielsen","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0190","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/jamacardio.2016.3311","article-title":"Cardiovascular biomarker score and clinical outcomes in patients with atrial fibrillation: a subanalysis of the ENGAGE AF-TIMI 48 randomized clinical trial","volume":"1","author":"Ruff","year":"2016","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0195","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/eurheartj\/ehw054","article-title":"The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation","volume":"37","author":"Hijazi","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0200","doi-asserted-by":"crossref","first-page":"f2573","DOI":"10.1136\/bmj.f2573","article-title":"Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study","volume":"346","author":"Hippisley-Cox","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0205","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/j.jacc.2007.07.076","article-title":"Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy","volume":"50","author":"Hohnloser","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0210","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/eurheartj\/ehn599","article-title":"Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation","volume":"31","author":"Friberg","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0215","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0735-1097(99)00489-1","article-title":"Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators","volume":"35","author":"Hart","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0220","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/eurheartj\/ehu359","article-title":"Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial","volume":"36","author":"Steinberg","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0225","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/eurheartj\/ehu307","article-title":"Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES","volume":"36","author":"Vanassche","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0230","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/eurheartj\/ehx042","article-title":"Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT","volume":"38","author":"Van Gelder","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0235","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.4022\/jafib.1475","article-title":"Stroke prevention for patients with atrial fibrillation: beyond the guidelines","volume":"9","author":"McIntyre","year":"2017","journal-title":"J. Atr. Fibrillation."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0240","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1161\/CIRCULATIONAHA.114.014058","article-title":"Long-term outcomes of secondary atrial fibrillation in the community: the Framingham Heart Study","volume":"131","author":"Lubitz","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0245","first-page":"361","article-title":"Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: retrospective cohort studies","volume":"k1717","author":"Adderley","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0250","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial","volume":"374","author":"Holmes","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial","volume":"64","author":"Holmes","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0260","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1016\/j.jacc.2017.10.021","article-title":"5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials","volume":"70","author":"Reddy","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0265","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4244\/EIJ-D-17-00493","article-title":"Left atrial appendage occlusion with the AMPLATZER Amulet device: periprocedural and early clinical\/echocardiographic data from a global prospective observational study","volume":"13","author":"Landmesser","year":"2017","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0270","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijcard.2015.11.181","article-title":"Comparison of Watchman device with new oral anti-coagulants in patients with atrial fibrillation: a network meta-analysis","volume":"205","author":"Koifman","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0275","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1160\/TH17-08-0555","article-title":"Regional differences in antithrombotic treatment for atrial fibrillation: insights from the GLORIA-AF phase II registry","volume":"117","author":"Mazurek","year":"2017","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0280","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1136\/heartjnl-2016-309741","article-title":"Stroke and death in elderly patients with atrial fibrillation in Japan compared with the United Kingdom","volume":"102","author":"Senoo","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0285","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.amjmed.2009.11.025","article-title":"Underuse of oral anticoagulants in atrial fibrillation: a systematic review","volume":"123","author":"Ogilvie","year":"2010","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0290","doi-asserted-by":"crossref","unstructured":"Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, et al. Antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation: the GLORIA-AF registry, phase II. Am. J. Med. 2015;128:1306\u201313 e1.","DOI":"10.1016\/j.amjmed.2015.07.013"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0295","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1093\/eurheartj\/ehw233","article-title":"Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF","volume":"37","author":"Bassand","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0300","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1136\/heartjnl-2016-309832","article-title":"Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation","volume":"103","author":"Camm","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0305","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1161\/STROKEAHA.116.012988","article-title":"Current status and time trends of oral anticoagulation use among Chinese patients with nonvalvular atrial fibrillation: the Chinese atrial fibrillation registry study","volume":"47","author":"Chang","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189495","article-title":"Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants: a nationwide population-based study","volume":"12","author":"Lee","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0315","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1378\/chest.13-0054","article-title":"Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score","volume":"144","author":"Apostolakis","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0320","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1160\/TH13-12-1007","article-title":"Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry","volume":"111","author":"Le Heuzey","year":"2014","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0325","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12913-018-2901-8","article-title":"Moving anticoagulation initiation and monitoring services into the community: evaluation of the Brighton and hove community pharmacy service","volume":"18","author":"Ingram","year":"2018","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0330","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.thromres.2017.07.007","article-title":"Factors influencing warfarin control in Australia and Singapore","volume":"157","author":"Bernaitis","year":"2017","journal-title":"Thromb. Res."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0335","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1007\/s11096-013-9796-6","article-title":"Comparing effectiveness of two anticoagulation management models in a Malaysian tertiary hospital","volume":"35","author":"Thanimalai","year":"2013","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0340","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11096-011-9597-8","article-title":"Anticoagulation control of pharmacist-managed collaborative care versus usual care in Thailand","volume":"34","author":"Saokaew","year":"2012","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0345","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jsha.2016.02.001","article-title":"Quality of anticoagulation control among patients with atrial fibrillation: an experience of a tertiary care center in Saudi Arabia","volume":"28","author":"Alyousif","year":"2016","journal-title":"J. Saudi Heart Assoc."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0350","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.4102\/phcfm.v8i1.1032","article-title":"Profile and anticoagulation outcomes of patients on warfarin therapy in an urban hospital in Cape Town, South Africa","volume":"8","author":"Sonuga","year":"2016","journal-title":"Afr. J. Prim. Health Care Fam. Med."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0355","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1253\/circj.CJ-15-0574","article-title":"Effects of regional differences in Asia on efficacy and safety of edoxaban compared with warfarin--insights from the ENGAGE AF-TIMI 48 trial","volume":"79","author":"Shimada","year":"2015","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0360","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/ageing\/afr097","article-title":"Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review","volume":"40","author":"Pugh","year":"2011","journal-title":"Age Ageing"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0365","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.amjmed.2016.05.041","article-title":"Evaluation of dose-reduced direct oral anticoagulant therapy","volume":"129","author":"Barra","year":"2016","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0370","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","article-title":"Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry","volume":"68","author":"Steinberg","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0375","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/j.jacc.2017.03.600","article-title":"Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction","volume":"69","author":"Yao","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0380","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jjcc.2018.03.009","article-title":"Appropriate doses of non-vitamin K antagonist oral anticoagulants in high-risk subgroups with atrial fibrillation: systematic review and meta-analysis","volume":"72","author":"Kim","year":"2018","journal-title":"J. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0385","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1161\/CIRCULATIONAHA.116.021831","article-title":"Management of bleeding with non-vitamin K antagonist oral anticoagulants in the era of specific reversal agents","volume":"134","author":"Ruff","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0390","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1161\/CIRCULATIONAHA.115.019628","article-title":"Idarucizumab: the antidote for reversal of dabigatran","volume":"132","author":"Eikelboom","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0395","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal - full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0400","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet alfa for the reversal of factor Xa inhibitor activity","volume":"373","author":"Siegal","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0405","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet alfa for acute major bleeding associated with factor Xa inhibitors","volume":"375","author":"Connolly","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0410","article-title":"Assessing bleeding risk in 4824 Asian patients with atrial fibrillation: the Beijing PLA Hospital atrial fibrillation project","volume":"6","author":"Guo","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0415","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/clc.22435","article-title":"The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis","volume":"38","author":"Zhu","year":"2015","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0420","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.amjmed.2015.10.001","article-title":"Evaluation of the HAS-BLED, ATRIA, and ORBIT bleeding risk scores in patients with atrial fibrillation taking warfarin","volume":"129","author":"Senoo","year":"2016","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0425","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijcard.2016.04.173","article-title":"Predictive ability of HAS-BLED, HEMORR2HAGES, and ATRIA bleeding risk scores in patients with atrial fibrillation. A French nationwide cross-sectional study","volume":"217","author":"Fauchier","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0430","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1055\/s-0038-1636534","article-title":"Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline, follow-up and Delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors","volume":"118","author":"Chao","year":"2018","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0435","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.amjmed.2017.09.009","article-title":"Comparing bleeding risk assessment focused on modifiable risk factors only versus validated bleeding risk scores in atrial fibrillation","volume":"131","author":"Guo","year":"2018","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0440","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1055\/s-0036-1597285","article-title":"Risk stratification models in atrial fibrillation","volume":"43","author":"Shahid","year":"2017","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0445","first-page":"3265","article-title":"Assessing bleeding risk in atrial fibrillation with the HAS-BLED and ORBIT scores: clinical application requires focus on the reversible bleeding risk factors","volume":"36","author":"Lip","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0450","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1160\/TH17-10-0710","article-title":"Assessing bleeding risk in atrial fibrillation patients: comparing a bleeding risk score based only on modifiable bleeding risk factors against the HAS-BLED score. The AMADEUS trial","volume":"117","author":"Esteve-Pastor","year":"2017","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0455","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijcard.2017.11.025","article-title":"Major bleeding and intracranial hemorrhage risk prediction in patients with atrial fibrillation: attention to modifiable bleeding risk factors or use of a bleeding risk stratification score? A nationwide cohort study","volume":"254","author":"Chao","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0460","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1161\/STROKEAHA.108.526988","article-title":"Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators","volume":"40","author":"van Walraven","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0465","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003432","article-title":"Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial","volume":"5","author":"Kato","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0470","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/CIRCULATIONAHA.117.031658","article-title":"Oral anticoagulation in very elderly patients with atrial fibrillation \u2014 a nationwide cohort study","volume":"138","author":"Chao","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0475","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1378\/chest.14-2414","article-title":"Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors","volume":"147","author":"Pastori","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0480","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.113.004834","article-title":"Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study","volume":"129","author":"Lamberts","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0485","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1093\/eurheartj\/ehu298","volume":"35","author":"Lip","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0490","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0495","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0500","first-page":"2018","author":"Lip","year":"2018","journal-title":"Europace"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0505","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ahj.2018.03.001","volume":"200","author":"Lopes","year":"2018","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0510","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ahj.2017.10.009","article-title":"Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: rationale and design of the ENTRUST-AF PCI trial","volume":"196","author":"Vranckx","year":"2018","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0515","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1378\/chest.15-1719","article-title":"Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies","volume":"149","author":"Dahal","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0520","first-page":"1","article-title":"Fitting the right non-vitamin K antagonist oral anticoagulant to the right patient with non-valvular atrial fibrillation: an evidence-based choice","author":"Li","year":"2018","journal-title":"Ann. Med."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0525","doi-asserted-by":"crossref","unstructured":"Nishimura M, Hsu JC. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and end-stage renal disease. Am. J. Cardiol. 2017.","DOI":"10.1016\/j.amjcard.2017.09.030"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0530","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1016\/j.jacc.2017.09.1091","article-title":"NOAC dosing in atrial fibrillation and renal dysfunction: what measure are you using?","volume":"70","author":"Shroff","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0535","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.cjca.2018.04.019","article-title":"Variability in non-vitamin K antagonist Oral anticoagulants dose adjustment in atrial fibrillation patients with renal dysfunction: the influence of renal function estimation formulae","volume":"34","author":"Andrade","year":"2018","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0540","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrneph.2018.19","article-title":"Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction","volume":"14","author":"Potpara","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0545","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.hrthm.2014.06.021","article-title":"Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis","volume":"11","author":"Chao","year":"2014","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0550","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12872-018-0804-6","article-title":"Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants","volume":"18","author":"Brinkmeier-Theofanopoulou","year":"2018","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0555","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1161\/CIRCULATIONAHA.113.006426","volume":"129","author":"Di Biase","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0560","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ijcard.2015.03.376","article-title":"Meta-analysis of major bleeding with uninterrupted warfarin compared to interrupted warfarin and heparin bridging in ablation of atrial fibrillation","volume":"187","author":"Nairooz","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0565","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ijcard.2018.03.095","article-title":"Continuous and minimally-interrupted direct oral anticoagulant are both safe compared with vitamin K antagonist for atrial fibrillation ablation: an updated meta-analysis","volume":"262","author":"Ha","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0570","series-title":"Eur. Heart J.","article-title":"Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation","author":"Kirchhof","year":"2018"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0575","first-page":"495","article-title":"Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation","volume":"377","author":"Calkins","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0580","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1056\/NEJMoa1302946","article-title":"Pacemaker or defibrillator surgery without interruption of anticoagulation","volume":"368","author":"Birnie","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0585","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/europace\/euu369","article-title":"The safety and efficacy of antithrombotic therapy in patients undergoing cardiac rhythm device implantation: a meta-analysis","volume":"17","author":"Yang","year":"2015","journal-title":"Europace"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0590","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ahj.2015.12.007","article-title":"Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: the BRUISE CONTROL-2 trial","volume":"173","author":"Essebag","year":"2016","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0595","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(16)31474-X","article-title":"Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial","volume":"388","author":"Goette","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0600","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1093\/eurheartj\/ehy148","article-title":"Apixaban compared to heparin\/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial","volume":"39","author":"Ezekowitz","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0605","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1093\/eurheartj\/ehu367","article-title":"Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation","volume":"35","author":"Cappato","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0610","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1161\/STROKEAHA.107.513200","article-title":"A systematic review of immediate anticoagulation for ischemic stroke of presumed cardioembolic origin","volume":"39","author":"Guedes","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0615","article-title":"Anticoagulants for acute ischaemic stroke","volume":"3","author":"Sandercock","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0620","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"45","author":"Kernan","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0625","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/europace\/eut083","article-title":"European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation","volume":"15","author":"Heidbuchel","year":"2013","journal-title":"Europace"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0630","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1001\/jamainternmed.2016.9369","article-title":"Outcomes associated with resuming warfarin treatment after hemorrhagic stroke or traumatic intracranial hemorrhage in patients with atrial fibrillation","volume":"177","author":"Nielsen","year":"2017","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0635","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/STROKEAHA.116.016327","article-title":"Restarting anticoagulant therapy after intracranial hemorrhage: a systematic review and meta-analysis","volume":"48","author":"Murthy","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0640","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1161\/CIRCULATIONAHA.115.019794","article-title":"Use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of intracranial hemorrhage","volume":"133","author":"Chao","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0645","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.vph.2016.05.012","article-title":"Resuming anticoagulant therapy after intracerebral bleeding","volume":"84","author":"Becattini","year":"2016","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0650","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/europace\/euv233","volume":"17","author":"Lane","year":"2015","journal-title":"Europace"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0655","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1160\/TH16-10-0787","article-title":"Patient values and preferences for antithrombotic therapy in atrial fibrillation. A narrative systematic review","volume":"117","author":"Loewen","year":"2017","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0660","first-page":"280","article-title":"The relative importance of barriers to the prescription of warfarin for nonvalvular atrial fibrillation","volume":"19","author":"Bungard","year":"2003","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0665","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.amjmed.2017.07.003","article-title":"Mobile health technology for atrial fibrillation management integrating decision support, education, and patient involvement: mAF App Trial","volume":"130","author":"Guo","year":"2017","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0670","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/eurheartj\/ehx762","article-title":"Telemonitoring-based feedback improves adherence to non-vitamin K antagonist oral anticoagulants intake in patients with atrial fibrillation","volume":"39","author":"Desteghe","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0675","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1093\/eurheartj\/ehu374","article-title":"Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry)","volume":"35","author":"Lip","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0680","first-page":"1947","article-title":"Integrated care in atrial fibrillation: a systematic review and meta-analysis","volume":"103","author":"Gallagher","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2018.09.057_bb0685","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","article-title":"The ABC pathway: an integrated approach to improve AF management","volume":"14","author":"Lip","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.057_bb0690","doi-asserted-by":"crossref","unstructured":"Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GY. Improved outcomes by integrated care of anticoagulated patients with atrial fibrillation using the simple ABC (atrial fibrillation better care) pathway. Am. J. Med. 2018:Epub.","DOI":"10.1016\/j.amjmed.2018.06.012"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527318321788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527318321788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T08:16:04Z","timestamp":1571904964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527318321788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":138,"alternative-id":["S0167527318321788"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2018.09.057","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stroke prevention in atrial fibrillation: State of the art","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2018.09.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}